Kerri Elyse Rieger

Title: Kerri Elyse Rieger: Innovator in Treatment Toxicity Assessment

Introduction

Kerri Elyse Rieger is a notable inventor based in Menlo Park, California. She has made significant contributions to the field of medical research, particularly in the assessment of treatment toxicity. Her innovative work has the potential to improve patient outcomes in cancer therapies.

Latest Patents

Kerri Elyse Rieger holds 1 patent titled "Methods and compositions for determining risk of treatment toxicity." This patent outlines methods for determining whether a patient treated with an anti-proliferative agent is susceptible to toxicity. The methods involve obtaining an expression profile for the transcriptional response to therapy from the patient and comparing it to a reference profile. This comparison helps in assessing the patient's susceptibility to toxicity. Additionally, the patent includes reagents and kits that facilitate the implementation of these methods.

Career Highlights

Kerri is affiliated with Leland Stanford Junior University, where she continues her research and development in the medical field. Her work is crucial in advancing personalized medicine and enhancing the safety of cancer treatments.

Collaborations

Kerri has collaborated with esteemed colleagues such as Wan-Jen Hong and Robert Tibshirani. These partnerships have further enriched her research and contributed to the development of innovative solutions in treatment assessment.

Conclusion

Kerri Elyse Rieger's contributions to the field of treatment toxicity assessment exemplify the impact of innovative research in medicine. Her work not only advances scientific knowledge but also holds promise for improving patient care in oncology.